Moreover, the cancer and leukemia group B (CALGB) 40601 trial reported a significant survival benefit for dual HER2-targeting with lapatinib and trastuzumab compared to the single anti-HER2 agents5,6. This evidence concerns the gene ERBB2 and cancer.